Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas”

92 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 92 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04533581
What this trial is testing

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Indolent B-cell Non-Hodgkin's Lymphoma
Kyowa Kirin Co., Ltd. 61
Early research (Phase 1)Active Not RecruitingNCT04447716
What this trial is testing

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Follicular LymphomaRecurrent Indolent Adult Non-Hodgkin Lymphoma+5 more
Thomas Jefferson University 4
Early research (Phase 1)Temporarily pausedNCT06824701
What this trial is testing

Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
University of Utah 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07477366
What this trial is testing

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

Who this might be right for
Relapsed B-Cell Non-Hodgkin Lymphoma
ImmunityBio, Inc. 20
Testing effectiveness (Phase 2)Study completedNCT02207062
What this trial is testing

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Transformed B-Cell Non-Hodgkin Lymphoma
University of Washington 20
Testing effectiveness (Phase 2)WithdrawnNCT00837174
What this trial is testing

Relapsed and/or Refractory Non-Hodgkin Lymphoma Study

Who this might be right for
Non-Hodgkin Lymphoma
The Methodist Hospital Research Institute
Testing effectiveness (Phase 2)Looking for participantsNCT07098364
What this trial is testing

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+9 more
Fred Hutchinson Cancer Center 33
Testing effectiveness (Phase 2)Study completedNCT01682044
What this trial is testing

Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma

Who this might be right for
Contiguous Stage II Grade 1 Follicular LymphomaContiguous Stage II Grade 2 Follicular LymphomaContiguous Stage II Grade 3 Follicular Lymphoma+30 more
Roswell Park Cancer Institute 20
Early research (Phase 1)Looking for participantsNCT06015880
What this trial is testing

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI) 30
Testing effectiveness (Phase 2)Study completedNCT00085696
What this trial is testing

VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Who this might be right for
B-Cell LymphomaFollicular LymphomaMarginal Lymphoma
Millennium Pharmaceuticals, Inc. 66
Testing effectiveness (Phase 2)WithdrawnNCT02653989
What this trial is testing

Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Lymphoma, Large B-Cell, DiffusePrimary Mediastinal Large B-cell LymphomaTransformed Indolent Lymphoma
Medivation, Inc.
Testing effectiveness (Phase 2)Study completedNCT02086175
What this trial is testing

Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

Who this might be right for
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
Dana-Farber Cancer Institute 25
Testing effectiveness (Phase 2)Looking for participantsNCT06458439
What this trial is testing

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Who this might be right for
Lymphoma, Non-HodgkinRelapsed Diffuse Large B Cell LymphomaRefractory Diffuse Large B-cell Lymphoma+2 more
Abramson Cancer Center at Penn Medicine 31
Testing effectiveness (Phase 2)Active Not RecruitingNCT03625037
What this trial is testing

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

Who this might be right for
DLBCLHigh-grade B-cell Lymphoma (HGBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)+6 more
Genmab 666
Testing effectiveness (Phase 2)Study completedNCT00093769
What this trial is testing

Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Jonsson Comprehensive Cancer Center 15
Testing effectiveness (Phase 2)Study completedNCT03583424
What this trial is testing

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Hematopoietic Cell Transplantation RecipientRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular Lymphoma+9 more
Ohio State University Comprehensive Cancer Center 19
Testing effectiveness (Phase 2)Study completedNCT00244985
What this trial is testing

Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Roswell Park Cancer Institute 42
Testing effectiveness (Phase 2)Study completedNCT00220285
What this trial is testing

Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's LymphomaLymphoma, B-CellLymphoma, Low-Grade
Bayer 45
Testing effectiveness (Phase 2)Study completedNCT00980395
What this trial is testing

Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma

Who this might be right for
LymphomaMantle Cell LymphomaIndolent Lymphoma+1 more
University of Arizona 24
Testing effectiveness (Phase 2)Study completedNCT00875056
What this trial is testing

Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)

Who this might be right for
Lymphoma
Merck Sharp & Dohme LLC 56
Load More Results